Why the study?
Does pharmacogenetic or platelet reactivity testing to tailor antiplatelet therapy improve outcomes differently in Asian versus Caucasian patients with acute coronary syndrome undergoing PCI?
Does pharmacogenetic or platelet reactivity testing to tailor antiplatelet therapy improve outcomes differently in Asian versus Caucasian patients with acute coronary syndrome undergoing PCI?
The East Asian paradox highlights the potential need for tailored antiplatelet therapy using pharmacogenetic and platelet reactivity testing to optimize outcomes across different ethnic populations.
No takes yet. Share an insight, caveat, or question.
Ethnic differences in post-PCI ischaemic and bleeding risks may require tailored antiplatelet strategies; leaves open whether pharmacogenetic testing improves outcomes.
Doreen Tan Su-Yin (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: